US loss of exclusivity · Immunology

Entyvio

Takeda

2032US biosimilars from
2025Today: 20262037
2025 worldwide sales
≈$6.0B
Date basis
Company guidance
US biosimilars
Filed with the FDA
Medicare price
Pending, from 2028
Pharma Patent Cliff by readouts.io Data checked 24 October 2026 · Full Entyvio timeline →